A novel effective treatment for menière’s disease - dextroamphetamine sulfate
Purpose: To determine if treatment with dextroamphetamine sulfate could ameliorate the symptoms of long-standing Menière’s disease in a menopausal woman with a past history of dysmenorrhea. Methods: Dextroamphetamine sulfate was started at 9.4 mg extended release tablets and eventually increased to...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2020-10-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/47/5/10.31083/j.ceog.2020.05.5238 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256564252835840 |
|---|---|
| author | J.H. Check D. Check R. Cohen |
| author_facet | J.H. Check D. Check R. Cohen |
| author_sort | J.H. Check |
| collection | DOAJ |
| description | Purpose: To determine if treatment with dextroamphetamine sulfate could ameliorate the symptoms of long-standing Menière’s disease in a menopausal woman with a past history of dysmenorrhea. Methods: Dextroamphetamine sulfate was started at 9.4 mg extended release tablets and eventually increased to 18.8 mg (Adzenys®). Results: The symptoms of constant ear fullness and severe tinnitus abated and have not returned for 2 years. In addition, the edema of the fingers and ankles have abated along with an 11 pound weight loss. Conclusions: Menière’s disease can be added to the long list of chronic treatment resistant conditions lumped together under the name of the increased cellular permeability syndrome. This syndrome may or may not be associated with pelvic pain. The common denominator is that these seemingly unrelated conditions affecting many organ systems all respond markedly well to amphetamine therapy. The hypothesis of the efficacy of dextroamphetamine sulfate is that it releases dopamine from sympathetic nerve fibers, which, in turn, diminishes cellular permeability. |
| format | Article |
| id | doaj-art-53bad1ade2f94c5aa0f5473de6a1fba5 |
| institution | OA Journals |
| issn | 0390-6663 |
| language | English |
| publishDate | 2020-10-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Clinical and Experimental Obstetrics & Gynecology |
| spelling | doaj-art-53bad1ade2f94c5aa0f5473de6a1fba52025-08-20T01:56:38ZengIMR PressClinical and Experimental Obstetrics & Gynecology0390-66632020-10-0147580780910.31083/j.ceog.2020.05.5238S0390-6663(20)00377-2A novel effective treatment for menière’s disease - dextroamphetamine sulfateJ.H. Check0D. Check1R. Cohen2Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, 08103 NJ, United StatesCooper institute for reproductive hormonal disorders, p.c. mt. laurel, 08054 NJ, United StatesCooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, 08103 NJ, United StatesPurpose: To determine if treatment with dextroamphetamine sulfate could ameliorate the symptoms of long-standing Menière’s disease in a menopausal woman with a past history of dysmenorrhea. Methods: Dextroamphetamine sulfate was started at 9.4 mg extended release tablets and eventually increased to 18.8 mg (Adzenys®). Results: The symptoms of constant ear fullness and severe tinnitus abated and have not returned for 2 years. In addition, the edema of the fingers and ankles have abated along with an 11 pound weight loss. Conclusions: Menière’s disease can be added to the long list of chronic treatment resistant conditions lumped together under the name of the increased cellular permeability syndrome. This syndrome may or may not be associated with pelvic pain. The common denominator is that these seemingly unrelated conditions affecting many organ systems all respond markedly well to amphetamine therapy. The hypothesis of the efficacy of dextroamphetamine sulfate is that it releases dopamine from sympathetic nerve fibers, which, in turn, diminishes cellular permeability.https://www.imrpress.com/journal/CEOG/47/5/10.31083/j.ceog.2020.05.5238menière’s diseaseincreased cellular permeability syndromedextroamphetamine sulfatedopaminedysmenorrhea |
| spellingShingle | J.H. Check D. Check R. Cohen A novel effective treatment for menière’s disease - dextroamphetamine sulfate Clinical and Experimental Obstetrics & Gynecology menière’s disease increased cellular permeability syndrome dextroamphetamine sulfate dopamine dysmenorrhea |
| title | A novel effective treatment for menière’s disease - dextroamphetamine sulfate |
| title_full | A novel effective treatment for menière’s disease - dextroamphetamine sulfate |
| title_fullStr | A novel effective treatment for menière’s disease - dextroamphetamine sulfate |
| title_full_unstemmed | A novel effective treatment for menière’s disease - dextroamphetamine sulfate |
| title_short | A novel effective treatment for menière’s disease - dextroamphetamine sulfate |
| title_sort | novel effective treatment for meniere s disease dextroamphetamine sulfate |
| topic | menière’s disease increased cellular permeability syndrome dextroamphetamine sulfate dopamine dysmenorrhea |
| url | https://www.imrpress.com/journal/CEOG/47/5/10.31083/j.ceog.2020.05.5238 |
| work_keys_str_mv | AT jhcheck anoveleffectivetreatmentformenieresdiseasedextroamphetaminesulfate AT dcheck anoveleffectivetreatmentformenieresdiseasedextroamphetaminesulfate AT rcohen anoveleffectivetreatmentformenieresdiseasedextroamphetaminesulfate AT jhcheck noveleffectivetreatmentformenieresdiseasedextroamphetaminesulfate AT dcheck noveleffectivetreatmentformenieresdiseasedextroamphetaminesulfate AT rcohen noveleffectivetreatmentformenieresdiseasedextroamphetaminesulfate |